Targeting endometriosis

Endometriosis is a common disorder, affecting ~10% of women worldwide. However, despite this high prevalence, treatment options are still very limited. Current treatments include surgery and hormone-based medications; however, these are often ineffective. As a result, large numbers of people are living with this debilitating condition. A new study reports early findings of a non-hormonal treatment that could be effective in endometriosis. Receptor tyrosine kinases (RTKs) might underlie some of the effects of endometriosis. Given that the FDA has approved pexidartinib (a tyrosine kinase inhibitor), Timothy Dunn and colleagues set out to determine whether this drug could be viable for use in endometriosis. This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue Buy this article - Purchase on SpringerLink - Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout References Original article Dunn, T. N. et al. Inhibition of CSF1R and KIT with pexidartinib reduces inflammatory signaling and cell viability in endometriosis. Endocrinology https://doi.org/10.1210/endocr/bqae003 (2024) Related article Girling, J. E. Harnessing the inflammatory processes in endometriosis. Nat. Rev. Endocrinol. 20, 69–70 (2024) Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Greenhill, C. Targeting endometriosis. Nat Rev Endocrinol 20, 193 (2024). https://doi.org/10.1038/s41574-024-00959-z Published: Version of record: Issue date: DOI: https://doi.org/10.1038/s41574-024-00959-z